In short
Clinical trials are currently underway to evaluate the safety and effectiveness of Aavanc80-5'Hotof, a groundbreaking gene therapy designed to treat sensorineural hearing loss caused by mutations in the otoferlin gene (OTOF). This innovative treatment aims to restore hearing in patients with this genetic condition by delivering a functional copy of the OTOF gene directly to the inner ear. The trials involve both initial treatment and long-term follow-up studies to assess the therapy's safety, efficacy, and potential long-term benefits for patients with this rare form of hearing loss.
At a glance
- Treatment
- Aavanc80-5'Hotof gene therapy
- Target Condition
- Sensorineural hearing loss due to otoferlin gene mutations
- Administration Method
- Intracochlear injection
- Age Group
- 2-17 years old
- Primary Objectives
- Assess safety, tolerability, and bioactivity of the therapy
- Secondary Objectives
- Evaluate long-term efficacy and improvements in hearing function
- Key Inclusion Criteria
- Confirmed biallelic OTOF mutations, profound bilateral hearing loss, preserved outer hair cell function
- Follow-up Duration
- Initial 1-year follow-up, with additional long-term study
- Primary Endpoints
- Adverse events, changes in ABR thresholds
- Secondary Endpoints
- Behavioral audiometry, speech recognition, auditory questionnaires
What is AAVAnc80-5'HOTOF?
AAVAnc80-5'HOTOF is an innovative gene therapy medication being developed to treat a specific type of hearing loss. It is part of a treatment called AAVAnc80-hOTOF, which consists of two components: AAVAnc80-5'HOTOF and AAVAnc80-3'HOTOF. This therapy is currently being studied in clinical trials to evaluate its safety and effectiveness.
How does it work?
AAVAnc80-hOTOF is a gene therapy that uses a special type of virus called AAV (adeno-associated virus) to deliver a healthy copy of the otoferlin gene (OTOF) to the inner ear. The therapy is designed to replace the faulty gene that causes hearing loss in some people.
The treatment uses a "dual vector approach", which means it uses two separate components (AAVAnc80-5'HOTOF and AAVAnc80-3'HOTOF) to deliver the complete gene. This is necessary because the OTOF gene is too large to fit into a single AAV vector.
What condition does it treat?
AAVAnc80-hOTOF is being developed to treat otoferlin gene-mediated hearing loss. This is a type of sensorineural hearing loss caused by mutations in the otoferlin gene. People with this condition typically have profound hearing loss from birth, which means they have very little or no hearing ability.
Clinical Trials
The treatment is currently being studied in clinical trials to determine its safety and effectiveness. There are two main studies:
- A Phase 1/2 trial (study number 2023-505128-76-00) that aims to assess the safety, tolerability, and initial effectiveness of AAVAnc80-hOTOF.
- A long-term follow-up study (study number 2024-512584-31-00) to evaluate the long-term safety and efficacy of the treatment.
Administration
AAVAnc80-hOTOF is administered through a procedure called intracochlear administration. This means the medication is delivered directly into the cochlea, which is part of the inner ear. The procedure is performed by a healthcare professional using a special delivery device.
Eligibility
The clinical trials have specific criteria for who can participate. Some key eligibility factors include:
- Age: Participants must be between 2 and 17 years old at the time of treatment.
- Genetic confirmation: Participants must have confirmed mutations in both copies of their OTOF gene.
- Hearing loss severity: Participants must have profound bilateral sensorineural hearing loss.
- Preserved outer hair cell function: This is assessed through a test called otoacoustic emissions (OAEs).
Safety and Efficacy
The main goals of the clinical trials are to assess the safety and effectiveness of AAVAnc80-hOTOF. Researchers are looking at:
- The frequency and types of side effects (adverse events) related to the treatment.
- Changes in hearing ability, measured through various hearing tests.
- Improvements in speech recognition and other hearing-related abilities.
Long-Term Follow-Up
Participants who receive AAVAnc80-hOTOF in the initial trial will be invited to participate in a long-term follow-up study. This study aims to monitor the safety and effectiveness of the treatment over an extended period. This is important because gene therapies can have long-lasting effects, and it's crucial to understand both the benefits and any potential risks over time.
In conclusion, AAVAnc80-5'HOTOF, as part of the AAVAnc80-hOTOF gene therapy, represents a promising approach to treating otoferlin gene-mediated hearing loss. While still in the clinical trial phase, this innovative treatment offers hope for individuals with this rare form of genetic hearing loss. As research continues, we will learn more about its safety, effectiveness, and long-term outcomes.